Compare FNKO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | TTRX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 281.2M |
| IPO Year | 2017 | N/A |
| Metric | FNKO | TTRX |
|---|---|---|
| Price | $5.55 | $9.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 571.0K | 99.8K |
| Earning Date | 05-07-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,209,000.00 | N/A |
| Revenue This Year | $4.42 | N/A |
| Revenue Next Year | $6.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $2.57 |
| 52 Week High | $6.09 | $11.69 |
| Indicator | FNKO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 72.90 |
| Support Level | $5.06 | $4.40 |
| Resistance Level | $5.87 | N/A |
| Average True Range (ATR) | 0.29 | 1.01 |
| MACD | -0.02 | 0.21 |
| Stochastic Oscillator | 53.25 | 64.31 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.